Dynamics of oxidative stress and urinary excretion of melatonin and its metabolites during acute ischemic stroke

Neuroscience Letters

Volumn 544, Issue , 2013, Pages 1-4

  Ritzenthaler, Thomas ^a   Lhommeau, Isabelle ^b   Douillard, Samuel ^b   Cho, Tea Hee ^a   Brun, Jocelyne ^c   Patrice, Thierry ^b   Nighoghossian, Norbert ^a,d   Claustrat, Bruno ^c,e  

^a Pierre Wertheimer Hospital   (France)

^b CHU de Nantes   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e INSERM   (France)

Author keywords

6 Sulfatoxymelatonin; Antioxidant; Melatonin; Oxidative stress; Stroke, AFMK

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; MELATONIN; MELATONIN DERIVATIVE; N1 ACETYL N2 FORMYL 5 METHOXYKYNURAMINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ADULT; AGED; BLOOD SAMPLING; BRAIN ISCHEMIA; CATABOLISM; CONTROLLED STUDY; FEMALE; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; URINALYSIS; URINARY EXCRETION;

AGED; COMORBIDITY; FEMALE; FRANCE; HUMANS; ISCHEMIA; MALE; MELATONIN; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PREVALENCE; REACTIVE OXYGEN SPECIES; RISK FACTORS; STROKE;

EID: 84878414930     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.073     Document Type: Note

References (27)

1. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., Marsh E.E. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
2. Allen C.L., Bayraktutan U. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke 2009, 4:461-470.
3. Beloosesky Y., Grinblat J., Laudon M., Grosman B.B., Streifler J.Y., Zisapel N. Melatonin rhythms in stroke patients. Neurosci. Lett. 2002, 319:103-106.
4. Benot S., Goberna R., Reiter R.J., Garcia-Mauriño S., Osuna C., Guerrero J.M. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J. Pineal Res. 1999, 27:59-64.
5. Bojkowski C.J., Arendt J., Shih M.C., Markey S.P. Melatonin secretion in humans assessed by measuring its metabolite, 6-sulfatoxymelatonin. Clin. Chem. 1987, 33:1343-1348.
6. Boutin J.A. Melatonin binding site MT3 is QR2. State of the art. J. Soc. Biol. 2007, 201:97-103.
7. Brun J., Claustrat B., David M. Urinary melatonin, LH, oestradiol, progesterone excretion during the menstrual cycle or in women taking oral contraceptives. Acta Endocrinol. 1987, 116:145-149.
8. Cervantes M., Moralí G., Letechipía-Vallejo G. Melatonin and ischemia-reperfusion injury of the brain. J. Pineal Res. 2008, 45:1-7.
9. Chern C.M., Liao J.F., Wang Y.H., Shen Y.C. Melatonin ameliorates neural function by promoting endogenous neurogenesis through the MT2 melatonin receptor in ischemic-stroke mice. Free Radic. Biol. Med. 2012, 52:1634-1647.
10. Claustrat B. Do time of day and genetics influence melatonin pharmacokinetics?. XI Congress of the European Biological Rhythms Society 2009, Oral Communication.
11. Fiorina P., Lattuada G., Ponari O., Silvestrini C., DallAglio P. Impaired nocturnal melatonin excretion and changes of immunological status in ischemic stroke patients. Lancet 1996, 347:692-693.
12. Fischer T.W., Sweatman T.W., Semak I., Sayre R.M., Wortsman J., Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J. 2006, 20:1564-1566.
13. Gariballa S.E., Hutchin T.P., Sinclair A.J. Antioxidant capacity after acute ischaemic stroke. Q. J. Med. 2002, 95:685-690.
14. Ghiselli A., Serafini M., Natella F., Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic. Biol. Med. 2000, 29:1106-1114.
15. Gomes A., Fernandes E., Lima L.J.F. Fluorescence probes used for detection of reactive oxygen species. J. Biochem. Biophys. Methods 2005, 65:45-80.
16. Harthé C., Claustrat B., Brun J., Chazot G. Direct 6-sulfatoxymelatonin radio-immunoassay in plasma with use of an iodinated tracer. Clin. Chem. 1991, 37:536-539.
17. Harthé C., Claudy D., Déchaud H., Vivien-Roels B., Pévet P., Claustrat B. Radioimmunoassay of N-acetyl-N-formyl-5-methoxykynuramine (AFMK): a melatonin oxidative metabolite. Life Sci. 2003, 73:1587-1597.
18. Lhommeau L., Douillard S., Bigot E., Benoit I., Krempf M., Patrice T. Serum resistance to singlet oxygen in patients with diabetes mellitus in comparison to healthy donors. Metab. Clin. Exp. 2011, 60:1340-1348.
19. Lin H.W., Lee E.J. Effects of melatonin in experimental stroke models in acute, sub-acute, and chronic stages. Neuropsychiatr. Dis. Treat. 2009, 5:157-162.
20. Nanetti L., Raffaelli F., Vignini A., Perozzi C., Silvestrini M., Bartolini M., Provinciali L., Mazzanti L. Oxidative stress in ischaemic stroke. Eur. J. Clin. Invest. 2011, 41:1318-2132.
21. Olivier D., Douillard S., Lhommeau I., Bigot E., Patrice T. Secondary oxidants in human serum exposed to singlet oxygen: the influence of hemolysis. Photochem. Photobiol. Sci. 2009, 8:1476-1486.
22. Pääkkönen T., Mäkinen T.M., Leppäluoto J., Vakkuri O., Rintamäki H., Palinkas L.A., Hassi J. Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions. J. Pineal Res. 2006, 40:110-115.
23. Rautiainen S., Larsson S., Virtamo J., Wolk A. Total antioxidant capacity of diet and risk of stroke: a population-based prospective cohort of women. Stroke 2012, 43:335-340.
24. Reiter R.J., Tan D.X., Fuentes-Broto L. Melatonin: a multitasking molecule. Prog. Brain Res. 2010, 181:127-151.
25. Ritzenthaler T N., Nighoghossian J., Berthiller A.M., Schott T.H., Cho L.D., Brun J., Claustrat B. Nocturnal urine melatonin and 6-sulphatoxymelatonin excretion at the acute stage of ischaemic stroke. J. Pineal Res. 2009, 46:349-352.
26. Tan D.X., Manchester L.C., Burkhardt S., Sainz R.M., Mayo J.C., Kohen R., Shohami E., Huo Y.S., Hardeland R., Reiter R.J. N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J. 2001, 15:2294-2296.
27. Tan D.X., Manchester L.C., Terron M.P., Flores L.J., Reiter R.J. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J. Pineal Res. 2007, 42:28-42.